Shares of engineered therapeutics specialist Ambrx Biopharma (NASDAQ:AMAM) skyrocketed on Monday following a major announcement. Pharmaceutical and medical technology stalwart Johnson & Johnson (NYSE:JNJ) will buy out the company, which should strengthen its oncology unit. Subsequently, AMAM stock doubled in price thanks to the win-win proposition.According to the accompanying press release, J&J will acquire all outstanding shares of Ambrx for $28 a pop in cash. That represents a 105% premium to the closing ...

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment.Ambrx is aiming to target multiple cancers with drugs called antibody-drug conjugates, or ADCs, which are described by researchers as "guided missiles" to directly target and kill cancer cells and minimize damage to healthy tissue.The deal, wh ...

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. Ambrx is advan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share AMAM Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ...

Call Start: 16:30 January 1, 0000 5:06 PM ET Ambrx Biopharma Inc. (NASDAQ:AMAM) Q4 2021 Earnings Conference Call April 26, 2022, 4:30 PM ET Company Participants Feng Tian – Chief Executive Officer Sonja Nelson – Chief Financial Officer Laurence Watts – Managing Director, Gilmartin Group Conference Call Participants Corinne Jenkins – Goldman Sachs Tazeen Ahmad – Bank of America Phil Nadeau – Cowen & Co. Joel Beatty – Baird Operator Welcome to the Ambrx Second Half and Full Year 2021 Financial Results and Co ...